- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03977662
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes (PARADIGM)
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Single-center, open label, non-randomized safety and efficacy trial to evaluate co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression.
A total of 8 patients will be enrolled in the study and followed for a minimum of 1 year up to 2 years after the last islet transplant, depending on enrollment date.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Patricia Brennan, RN, PhD
- Phone Number: 415-476-3229
- Email: Patricia.Brennan@ucsf.edu
Study Contact Backup
- Name: Rodney Rogers
- Phone Number: 415-514-6454
- Email: Rodney.Rogers@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California
-
Contact:
- Patricia Brennan, RN, PhD
- Phone Number: 415-476-3229
- Email: Patricia.Brennan@ucsf.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female subjects age 18 or older.
- Subjects who are able to provide written informed consent and to comply with study procedures.
- Clinical history compatible with Type 1 diabetes (onset < 40 yrs old and insulin dependent for > 5 yrs at enrollment, c-peptide negative).
- Recipients should have absent stimulated c-peptide (< 0.3 ng/mL) in response to a (Boost® 6 mL/kg BW to a maximum of 360 mL; another equivalent product), measured at 60 and 90 min after start of consumption.
- Subjects who are > 6 months post-renal transplant or >6 months post-liver transplant who are taking appropriate calcineurin inhibitor (CNI) based maintenance immunosuppression ([tacrolimus alone or in conjunction with sirolimus, mycophenolate mofetil, myfortic, or azathioprine; or cyclosporine in conjunction with sirolimus, mycophenolate mofetil, or myfortic ± Prednisone ≤ 10 mg/day).
- Stable renal function as defined by a creatinine of no more than one third greater than the average creatinine determination performed in the 6 previous months prior to islet transplant, as well as absence of a rejection episode in the 6 months prior to islet transplant
- Stable liver function tests as defined by: SGOT (AST), SGPT (ALT), alkaline phosphatase values < 1.5, or total bilirubin < 1.5 times normal upper limits at time of study entry, as well as absence of a rejection episode in the 6 months prior to islet transplant
Exclusion Criteria:
- Presence of donor specific anti-HLA antibodies detected by Luminex Single Antigen/specificity bead assay including weakly reactive antibodies that would not be detected by a flow cross match
- Insulin requirement of >1.0 IU/kg/day
- Weight more than 100 kg or body mass index (BMI) > 30 kg/m2.
- Primary hyperparathyroidism OR secondary hyperparathyroidism
- Untreated or unstable proliferative diabetic retinopathy.
- Blood Pressure: SBP > 180 mmHg or DBP >100 mmHg despite treatment with antihypertensive agents.
- Calculated GFR of ≤ 40 mL/min/1.73 m2 using the subject's measured serum creatinine and the Chronic Kidney Disease Epidemiology Collaboration (CKD- EPI) equation, as well as presence of a rejection episode in the 6 months prior to islet transplant
- Elevated liver function tests as defined by: SGOT (AST), SGPT (ALT), alkaline phosphatase values > 1.5, or total bilirubin >1.5 times normal upper limits at time of study entry, as well as presence of a rejection episode in the 6 months prior to islet transplant
- Proteinuria (albumin/creatinine ratio or ACr > 300mg/g) of new onset since kidney transplantation.
- For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo- Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.
- Active infection including hepatitis B, hepatitis C, HIV, or TB. Quantiferon gold assay will be used to determine TB infection.
- Invasive aspergillus, histoplasmosis, and coccidioidomycosis infection within 1 year prior to study entry.
- Any history of malignancy following receiving either the kidney or liver transplant, except for completely resected squamous or basal cell carcinoma of the skin
- Known active alcohol or substance abuse.
Severe co-existing cardiac disease, characterized by any one of these conditions:
- Recent MI (within past 6 months),
- Evidence of ischemia on functional cardiac exam within the last year,
- Left ventricular ejection fraction < 30%,
- Valvular disease requiring replacement with prosthetic valve.
- Active infections (except mild skin and nail fungal infections).
- Active peptic ulcer disease or gastritis, symptomatic gallstones, or portal hypertension.
- Use of any investigational agents within 4 weeks of enrollment.
- Administration of live attenuated vaccine(s) within 2 months of enrollment.
- Any medical condition that, in the opinion of the investigator, will interfere with safe study completion.
- Positive screen for BK viremia at time of screening.
- Untreated hyperlipidemia - TC > 200 mg/dL, TGC > 200 mg/dL, LDL > 130 mg/dL
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PTG with adult pancreatic islet co-transplantation
People with Type 1 (c-peptide negative) diabetes with stable kidney or liver allografts on chronic immunosuppression who receive study intervention, which is co-transplantation of allogeneic parathyroid (PTG) with adult pancreatic islets in people with Type 1 diabetes in the intramuscular (IM) site
|
Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Minimum of 1 year up to 2 years depending on transplant date
|
Safety: Since this study is a pilot non-randomized safety and efficacy trial with patient enrollment limited by budgetary constraints, no direct statistical significance tests can be performed.
|
Minimum of 1 year up to 2 years depending on transplant date
|
Incidence of post-transplant infections and malignancies
Time Frame: Minimum of 1 year up to 2 years depending on transplant date
|
Safety: Since this study is a pilot non-randomized safety and efficacy trial with patient enrollment limited by budgetary constraints, no direct statistical significance tests can be performed.
|
Minimum of 1 year up to 2 years depending on transplant date
|
Incidence of de novo sensitization
Time Frame: Minimum of 1 year up to 2 years depending on transplant date
|
Safety: Since this study is a pilot non-randomized safety and efficacy trial with patient enrollment limited by budgetary constraints, no direct statistical significance tests can be performed.
|
Minimum of 1 year up to 2 years depending on transplant date
|
Incidence of Insulin independence
Time Frame: Minimum of 1 year up to 2 years depending on transplant date
|
Efficacy: Incidence of participants no longer using insulin
|
Minimum of 1 year up to 2 years depending on transplant date
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic control
Time Frame: Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2
|
Assessed by measuring HbA1c using high-performance liquid chromatography
|
Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2
|
Glycemic lability
Time Frame: Day 75, Day 180, Day 270, Year 1
|
Assessed with the Mean Amplitude of Glycemic Excursions (MAGE) test
|
Day 75, Day 180, Day 270, Year 1
|
Hypoglylcemic episodes: Clarke Survey Score
Time Frame: Day 75, Day 180, Day 270, Year 1
|
The Clarke survey will be used to assess the frequency and severity of hypoglycemic episodes
|
Day 75, Day 180, Day 270, Year 1
|
Hypoglylcemic episodes: Hypo Score
Time Frame: Day 75, Day 180, Day 270, Year 1
|
The HYPO score will be used to assess the frequency and severity of hypoglycemic episodes
|
Day 75, Day 180, Day 270, Year 1
|
Beta cell function as assessed by Mixed Meal Tolerance Test (MMTT)
Time Frame: Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2
|
Results from both MMTT and FSIGT will be used to assess beta cell function
|
Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2
|
Beta cell function as assessed by Insulin-Modified Frequently-Sampled Intravenous Glucose ToleranceTest (FSIGT)
Time Frame: Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2
|
Results from both MMTT and FSIGT will be used to assess beta cell function
|
Day 75, Day 180, Day 270, Year 1, Year 1.5, Year 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Peter Stock, MD, PhD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-26725
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Co-transplantation of PTG with pancreatic islets
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Wyeth...UnknownDiabetes Mellitus, Type 1United States
-
Emory UniversityJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus, Type 1United States
-
Technische Universität DresdenGerman Cancer Research Center; KKS DresdenNot yet recruitingPeriampullary Cancer | Postoperative Pancreatic FistulaGermany
-
Frantisek SaudekCompleted
-
Corline Biomedical ABUnknown
-
Jinling Hospital, ChinaUnknownInflammatory Bowel DiseaseChina
-
Erasme University HospitalCompleted
-
Hillel Yaffe Medical CenterUnknown
-
National Institute of Allergy and Infectious Diseases...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Dongsik ChaeUnknownOsteoarthritis | Genu VarumKorea, Republic of